FTC targets insulin, threatening to go after PBM-pharma deals that steer into 'commercial bribery'

The Federal Trade Commission voted unanimously yesterday (5-0) to adopt a new policy specifically targeting rising insulin prices, but also putting drug companies and the PBM middlemen on notice that paying rebates and fees to exclude cheaper generics can violate competition and consumer protection laws.